Skip to content

Upper Extremity Rehabilitation Using SMART Glove System With Transcranial Direct Current Stimulation

Distal Upper Extremity Rehabilitation Using SMART Glove System With Transcranial Direct Current Stimulation (tDCS) for Stroke Patients : a Double-blinded, Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03465631
Enrollment
20
Registered
2018-03-14
Start date
2016-08-09
Completion date
2018-03-31
Last updated
2018-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke rehabilitation

Brief summary

The aim of this study to investigate the effect of combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke. We hypothesized that experimental group (VR-based training with dual-tDCS) would improve distal upper extremity function rather than control group (VR-based training with dual sham tDCS).

Detailed description

This is a double-blind, randomized controlled study. Patients were randomly assigned to 1 : 1 ratio to experimental group (VR-based training with dual-tDCS; VR-Dual) or the control group (VR-based training with dual sham tDCS; VR-Sham) . For both conditions, VR-Dual and VR-Sham group commenced at the same time (20 minutes). The therapist and patients were blinded as to whether the patients received real or sham tDCS. The study was approved by the Ethics Committee of the National Rehabilitation Center, Korea, and all participants provided written informed consent before enrollment.

Interventions

DEVICESMART Glove system with tDCS

combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.

DEVICESMART Glove system with sham-tDCS

combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.

Sponsors

National Rehabilitation Center, Seoul, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* first-time ischemic or hemorrhagic stroke * unilateral upper extremity functional deficits after stroke * presence of a score of at least 3 points on the Medical Research Council (MRC) * a score ≥ 4 on the Brunnstrom stage * a score ≥ 25 on the Korean version of the Mini-Mental Status Exam (K-MMSE)

Exclusion criteria

* age \< 20 years * wrist and finger spasticity with the Modified Ashworth Scale (MAS) score ≥ 2 * uncontrolled hypertension, heart problems, infection, or any history of seizure or epilepsy * neurological disorders that cause motor deficits * being unable to perform the task or to understand instructions * presence of pacemaker, pregnancy, cognitive impairment, or psychiatric disorders

Design outcomes

Primary

MeasureTime frameDescription
Box and block testbaseline (T0), pre-intervention after 1 week of baseline (T1), after 5 weeks of intervention (T2), and at 4 weeks post-intervention (T3)Change of box and block test scores

Secondary

MeasureTime frameDescription
Fugl-Meyer assessment of the upper extremity (FMA)baseline (T0), pre-intervention after 1 week of baseline (T1), after 5 weeks of intervention (T2), and at 4 weeks post-intervention (T3)Change of FMA scores
Jebsen Taylor Hand Function Test (JTT)baseline (T0), pre-intervention after 1 week of baseline (T1), after 5 weeks of intervention (T2), and at 4 weeks post-intervention (T3)Change of JTT scores
Grip strengthbaseline (T0), pre-intervention after 1 week of baseline (T1), after 5 weeks of intervention (T2), and at 4 weeks post-intervention (T3)Change of Grip strength (JAMAR) scores
Stroke Impact Scale (SIS)pre-intervention after 1 week of baseline (T1), after 5 weeks of intervention (T2)Change of SIS scores

Countries

South Korea

Contacts

Primary ContactJoon-Ho Shin, MS
asfreelyas@gmail.com82-2-901-1884

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026